Department of Clinical and Molecular Pathology, Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic.
J Clin Pathol. 2011 Nov;64(11):977-82. doi: 10.1136/jclinpath-2011-200106. Epub 2011 Jul 8.
Collagen triple helix repeat containing 1 (CTHRC1) affects Wnt signalling, collagen deposition and bone formation. It is an extracellular matrix protein which is also abnormally expressed in the tumour microenvironment. CTHRC1 has not been studied in breast cancer by immunohistochemistry.
To examine expression of CTHRC1 together with periostin and versican in breast cancer patients and investigate its association with clinicopathological characteristics.
The formalin-fixed paraffin-embedded tissues of 173 invasive carcinomas (classified into WHO histotypes and luminal, triple negative and Her2 subtypes), as well as normal tissues, precursor lesions and metastatic lymph nodes were stained by relevant antibodies, assessed semiquantitatively by histoscore and statistically evaluated.
Expression of CTHRC1, versican and periostin was significantly higher in breast cancer than in normal tissue or precursor lesions. CTHRC1 stromal expression was enhanced in triple negative cases and also in patients with bone metastasis. Periostin expression was high in primary tumours, in particular triple negative ones, and also in their lymph node metastases. Cox regression analysis showed that in patients with high periostin, the risk of bone metastases increased with increased CTHRC1 expression.
CTHRC1 and periostin play important roles in breast cancer progression. These preliminary results show that combined evaluation of CTHRC1 and periostin could serve as a potential marker for breast cancer bone metastasis; the other observations contribute to the description of the tumour microenvironment, with implications for lymph node and bone metastasis.
富含三螺旋重复序列的胶原蛋白 1（CTHRC1）可影响 Wnt 信号转导、胶原蛋白沉积和骨形成。它是一种细胞外基质蛋白，在肿瘤微环境中也异常表达。CTHRC1 尚未通过免疫组织化学在乳腺癌中进行研究。
检测 CTHRC1 与骨桥蛋白和 versican 在乳腺癌患者中的表达，并探讨其与临床病理特征的关系。
使用相关抗体对 173 例浸润性癌（分为 WHO 组织学类型和管腔型、三阴性型和 Her2 型）的福尔马林固定石蜡包埋组织以及正常组织、前体病变和转移性淋巴结进行染色，通过组织评分进行半定量评估，并进行统计学评价。
与正常组织或前体病变相比，CTHRC1、versican 和骨桥蛋白在乳腺癌中的表达明显升高。三阴性病例和骨转移患者的 CTHRC1 基质表达增强。原发肿瘤中periostin 表达较高，特别是三阴性肿瘤，其淋巴结转移中也较高。Cox 回归分析显示，periostin 高表达的患者，随着 CTHRC1 表达的增加，发生骨转移的风险增加。
CTHRC1 和 periostin 在乳腺癌的进展中发挥重要作用。这些初步结果表明，联合评估 CTHRC1 和 periostin 可能作为乳腺癌骨转移的潜在标志物；其他观察结果有助于描述肿瘤微环境，对淋巴结和骨转移具有重要意义。
